rheumatoid arthritis

FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
Xconomy
Eli Lilly
FDA
advisory panels
rheumatoid arthritis
baricitinib
Incyte
Flag link:
Big Week Ahead for Eli Lilly: Here's What to Look For
Big Week Ahead for Eli Lilly: Here's What to Look For
Motley Fool
Eli Lilly
earnings
FDA
Incyte
olumiant
rheumatoid arthritis
Flag link:
3 Biotech Stocks With Major Catalysts Incoming
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Incyte
TG Therapeutics
Cara Therapeutics
CR845
opioids
ublituximab
leukemia
olumiant
rheumatoid arthritis
Flag link:
Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms
Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms
Xconomy
Eli Lilly
baricitinib
olumiant
rheumatoid arthritis
Flag link:
With study success, AbbVie's arthritis hopeful looks to be a safer bet
With study success, AbbVie's arthritis hopeful looks to be a safer bet
Biopharma Dive
AbbVie
rheumatoid arthritis
Upadacitinib
Humira
clinical trials
Flag link:
Hydrogel delivery enables long-lasting, ‘flare-responsive’ arthritis treatment
Hydrogel delivery enables long-lasting, ‘flare-responsive’ arthritis treatment
Fierce Biotech
Alivio Therapeutics
hydrogels
rheumatoid arthritis
Flag link:
Positive momentum for biotech Incyte
Positive momentum for biotech Incyte
GoinPharma
Inctye
olumiant
baricitinib
rheumatoid arthritis
Flag link:
This 3D-printed device analyzes tissue cells from rheumatoid arthritis
This 3D-printed device analyzes tissue cells from rheumatoid arthritis
Medical Design and Outsourcing
3D printing
rheumatoid arthritis
diagnostics
Flag link:
$690M deal in peril after Lilly ends mid-stage studies
$690M deal in peril after Lilly ends mid-stage studies
Biopharma Dive
Eli Lilly
clinical trials
rheumatoid arthritis
Btk inhibitors
Hanmi Pharmaceutical
LY3337641/HM71224
Flag link:
Eli Lilly shutters a failed PhII for rheumatoid arthritis, clouding $690M Hanmi pact
Eli Lilly shutters a failed PhII for rheumatoid arthritis, clouding $690M Hanmi pact
Endpoints
Eli Lilly
rheumatoid arthritis
Hanmi Pharmaceutical
clinical trials
Flag link:
Why AbbVie's Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis
Why AbbVie's Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis
Market Realist
AbbVie
Upadacitinib
rheumatoid arthritis
Flag link:
Another death mars AbbVie’s latest batch of promising data for its star rheumatoid arthritis drug
Another death mars AbbVie’s latest batch of promising data for its star rheumatoid arthritis drug
BioPharma Dive
AbbVie
rheumatoid arthritis
Upadacitinib
ABT-494
Flag link:
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval
Yahoo/Reuters
Pfizer
biosimilars
JNJ
Remicade
Ifixi
rheumatoid arthritis
Crohn's Disease
Flag link:
Amgen launches Enbrel Mini single-dose cartridges with reusable auto-injector
Amgen launches Enbrel Mini single-dose cartridges with reusable auto-injector
Drug Delivery Business News
Amgen
Enbrel Mini
auto-injectors
rheumatoid arthritis
Flag link:
Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy
Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy
Yahoo/Reuters
Janssen
Samsung Bioepis
Remicade
biosimilars
rheumatoid arthritis
Flag link:
Could pain data give Lilly's baricitinib back its edge?
Could pain data give Lilly's baricitinib back its edge?
BioPharma Dive
Eli Lilly
baricitinib
Humira
AbbVie
rheumatoid arthritis
Flag link:
J&J is jettisoning two of its promised blockbuster drugs, and it couldn’t come at a worse time
J&J is jettisoning two of its promised blockbuster drugs, and it couldn’t come at a worse time
Endpoints
JNJ
sirukumab
rheumatoid arthritis
talacotuzumab
acute myeloid leukemia
Flag link:
Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis
Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis
Market Realist
Sanofi
Kevzara
rheumatoid arthritis
Regeneron
Flag link:
FDA spurns J&J’s troubled rheumatoid arthritis drug sirukumab
FDA spurns J&J’s troubled rheumatoid arthritis drug sirukumab
Endpoints
FDA
JNJ
rheumatoid arthritis
sirukumab
Flag link:
AbbVie keen on JAK inhibitor despite safety concerns
AbbVie keen on JAK inhibitor despite safety concerns
BioPharma Dive
AbbVie
JAK inhibitors
Upadacitinib
ABT-494
rheumatoid arthritis
Flag link:

Pages